Acute rhinosinusitis : a pharmacoeconomic review of antibacterial use
- PMID: 15329029
- DOI: 10.2165/00019053-200422130-00002
Acute rhinosinusitis : a pharmacoeconomic review of antibacterial use
Abstract
Acute rhinosinusitis is a common disease, in both children and adult patients, and happens most often in the setting of a viral infection with or without bacterial superinfection. Although spontaneous resolution is common, antibacterials are often prescribed and have a tremendous impact on costs, either directly or through the emergence of resistance in causative or colonising micro-organisms. The purpose of this work was to review published literature from 1989 to 2002 on antibacterial treatment in acute rhinosinusitis from a clinical and economical perspective. A relatively small number of studies have compared antibacterials with placebo and few have suggested that antibacterials are superior to placebo, except when a bacterial cause is established or in the presence of specific CT-scan findings. On the other hand, 58 randomised controlled trials were published between 1989 and 2002, that compared the relative efficacy of various antibacterials. Most of these studies had serious methodological flaws, and no single antibacterial proved superior to its comparators. Economic data are scarce and indicate cost of disease is high. Of the different treatment strategies assessed symptomatic treatment (patients being treated with antibacterials only if they failed to improve after 7 days) was the most cost-effective approach, compared with treating patients on the basis of specific clinical criteria, empirical treatment (all patients initially treated with antibacterials), or radiology-guided treatment. Cost effectiveness varied with disease prevalence. In conclusion, this pharmacoeconomic review of antibacterial use in acute rhinosinusitis shows the need for improvement in the quality of the studies feeding economic analyses, but suggests that huge financial interests are at stake. Savings achievable, by better targeting patients needing antibacterial treatment, could be substantial, and more practical and precise diagnostic procedures are clearly needed. Acute rhinosinusitis is a typical example of a clinical dilemma in which good clinical practice must be balanced against imperfect information and patients' individual interests balanced against society's interest.
Similar articles
-
Treatment modalities for bacterial rhinosinusitis.Expert Opin Pharmacother. 2010 Apr;11(5):755-69. doi: 10.1517/14656561003598901. Expert Opin Pharmacother. 2010. PMID: 20201730 Review.
-
Cost analysis in the diagnosis of chronic rhinosinusitis.Am J Rhinol. 2003 May-Jun;17(3):139-42. Am J Rhinol. 2003. PMID: 12862401
-
[Efficacy and safety of mometasone furoate nasal spray in the treatment of sinusitis or acute rhinosinusitis].Rev Laryngol Otol Rhinol (Bord). 2007;128(3):187-92. Rev Laryngol Otol Rhinol (Bord). 2007. PMID: 18323331 French.
-
Pharmacological treatments for rhinosinusitis.Expert Opin Pharmacother. 2002 Mar;3(3):305-13. doi: 10.1517/14656566.3.3.305. Expert Opin Pharmacother. 2002. PMID: 11866681 Review.
-
Acute sinusitis: guide to selection of antibacterial therapy.Drugs. 2004;64(8):805-19. doi: 10.2165/00003495-200464080-00002. Drugs. 2004. PMID: 15059037
Cited by
-
Cost-effectiveness of mometasone furoate nasal spray in the treatment of acute rhinosinusitis.Prim Care Respir J. 2012 Dec;21(4):412-8. doi: 10.4104/pcrj.2012.00085. Prim Care Respir J. 2012. PMID: 23000911 Free PMC article. Clinical Trial.
-
Comprehensive Review of Cyclamen: Development, Bioactive Properties, and Therapeutic Applications.Pharmaceuticals (Basel). 2024 Jun 27;17(7):848. doi: 10.3390/ph17070848. Pharmaceuticals (Basel). 2024. PMID: 39065699 Free PMC article. Review.
-
Factors affecting the cost effectiveness of antibiotics.Chemother Res Pract. 2011;2011:249867. doi: 10.1155/2011/249867. Epub 2011 Feb 6. Chemother Res Pract. 2011. PMID: 22312550 Free PMC article.
-
Health Economics of Antibiotics.Pharmaceuticals (Basel). 2010 Apr 29;3(5):1348-1359. doi: 10.3390/ph3051348. Pharmaceuticals (Basel). 2010. PMID: 27713306 Free PMC article. Review.
-
Preclinical evaluation of Luffa operculata Cogn. and its main active principle in the treatment of bacterial rhinosinusitis.Braz J Otorhinolaryngol. 2016 Dec 26;84(1):82-8. doi: 10.1016/j.bjorl.2016.11.004. Online ahead of print. Braz J Otorhinolaryngol. 2016. PMID: 28126352 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical